The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120

بواسطة Nicos Karasavvas, Erik Billings, Mangala Rao, Constance Williams, Susan Zolla-Pazner, Robert T. Bailer, Richard A. Koup, Sirinan Madnote, Duangnapa Arworn, Xiaoying Shen, Georgia D. Tomaras, Jeffrey R. Currier, Mike Jiang, Craig Magaret, Charla Andrews, Raphael Gottardo, Peter Gilbert, Timothy J. Cardozo, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Robert Paris, Kelli Greene, Hongmei Gao, Sanjay Gurunathan, Jim Tartaglia, Faruk Sinangil, Bette T. Korber, David C. Montefiori, John R. Mascola, Merlin L. Robb, Barton F. Haynes, Viseth Ngauy, Nelson L. Michael, Jerome H. Kim, Mark S. De Souza
منشور في 2018